Syndax Pharmaceuticals, Inc. — Cyborg Score 8/10

Strategic Profile

Syndax generated over $275 million in 2025 sales across its two lead products, demonstrating strong commercial execution and market penetration. The company initiated REVEAL-ND, a Phase 3 trial of revumenib in newly diagnosed NPM1m AML patients, designed to support both accelerated and full FDA approval.

Cyborg Score Rationale

Analyst consensus rates SNDX as "Strong Buy" with an average 12-month price target of $36.92, representing 76% upside. The company has achieved rapid commercial ramp with two approved drugs generating significant revenue momentum, though it remains pre-profitable.

Top Insights

• Revuforj was named Best New Drug at the Scrip Awards 2025, recognizing excellence in pharmaceutical development.
• Q4 2025 Revuforj revenue reached $44.2M (38% sequential growth) and Niktimvo reached $56.0M (22% sequential growth), indicating accelerating adoption.
• Syndax initiated a multi-regional Managed Access Program enabling Revuforj prescriptions outside the U.S. where local regulations permit.
• The company had $394.1M in cash at year-end 2025 with 2026 R&D and SG&A expected at ~$400M while targeting profitability from product revenue.

Named Competitors

• Menin Inhibitor Pipeline — Various menin inhibitors in development across multiple companies
• CSF-1R Inhibitors — Competing mechanisms for chronic GVHD treatment

Recent Developments

• (Feb 2026) Preliminary 2025 financial results show $172.4M revenue from two launched drugs with accelerating quarterly growth
• (Dec 2025) Revuforj received Best New Drug award at Scrip Awards 2025 for therapeutic advance
• (Nov 2025) Initiated Phase 3 REVEAL-ND trial of revumenib in newly diagnosed NPM1m AML with dual approval endpoints

Open the full interactive Syndax Pharmaceuticals, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.